Comparison of Nuclear Medicine Therapeutics Targeting PSMA among Alpha-Emitting Nuclides.
PSMA
actinium-225
astatine-211
cytotoxicity
double strand brake
reproductive capability
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
11 Jan 2024
11 Jan 2024
Historique:
received:
30
11
2023
revised:
05
01
2024
accepted:
07
01
2024
medline:
23
1
2024
pubmed:
23
1
2024
entrez:
23
1
2024
Statut:
epublish
Résumé
Currently, targeted alpha therapy (TAT) is a new therapy involving the administration of a therapeutic drug that combines a substance of α-emitting nuclides that kill cancer cells and a drug that selectively accumulates in cancer cells. It is known to be effective against cancers that are difficult to treat with existing methods, such as cancer cells that are widely spread throughout the whole body, and there are high expectations for its early clinical implementation. The nuclides for TAT, including
Identifiants
pubmed: 38256007
pii: ijms25020933
doi: 10.3390/ijms25020933
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Agency for Medical Research and Development
ID : JP23ym0126091
Organisme : JAEA and the GIMRT Collaborative Research Program of the Institute for Materials Research, Tohoku University
ID : 202212-RDKGE-0046